Comparative Pharmacology
Head-to-head clinical analysis: EPIPEN versus EPIPEN JR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPIPEN versus EPIPEN JR.
EPIPEN vs EPIPEN JR.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonselective alpha-1, alpha-2, beta-1, beta-2, beta-3 adrenergic receptor agonist; causes vasoconstriction (alpha-1), bronchodilation (beta-2), and increased cardiac contractility and heart rate (beta-1).
Epinephrine is a direct-acting sympathomimetic amine that acts on alpha- and beta-adrenergic receptors. Alpha-adrenergic effects include vasoconstriction, which reduces edema and increases blood pressure. Beta-adrenergic effects include bronchodilation, positive inotropic and chronotropic cardiac effects, and inhibition of histamine release from mast cells.
0.3 mg intramuscularly (lateral thigh) every 5-15 minutes as needed for anaphylaxis.
Epinephrine 0.3 mg intramuscularly in the mid-outer thigh every 5-15 minutes as needed for anaphylaxis.
None Documented
None Documented
2-3 minutes (IV); clinical context: ultra-short half-life necessitates repeated doses or continuous infusion for sustained effect
Terminal elimination half-life is approximately 2-3 minutes following intravenous administration. Clinically, the short half-life necessitates repeat dosing or continuous infusion for sustained effect. After intramuscular injection, absorption is slower, and the effective half-life is longer due to continued absorption.
Renal (90% as metabolites, 10% unchanged); biliary/fecal (<5%)
Epinephrine is rapidly metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). The metabolites, including metanephrine and vanillylmandelic acid (VMA), are primarily excreted renally. About 85-90% of an administered dose is eliminated in the urine within 24 hours, with less than 5% excreted unchanged. Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Adrenergic Agonist
Adrenergic Agonist